Abbott Laboratories (ABT) said Thursday it has launched a clinical trial aimed at evaluating the impact of earlier intervention using its HeartMate 3 left ventricular assist device, or heart pump, in patients with advanced heart failure.
The study, targeted to enroll up to 850 patients at 75 global sites, will use Abbott's CardioMEMS HF System sensor to monitor pulmonary artery pressures and identify patients who may benefit from early intervention with the HeartMate 3 heart pump, according to Abbott.
Abbott said enrollment will start shortly in the US. The study will assess primary and secondary endpoints after two years and continue monitoring participants for up to five years, the company added.
Price: 116.66, Change: -0.35, Percent Change: -0.30
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。